UBS assumed coverage of Arcellx (ACLX) with a Buy rating and $100 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- 3 ‘Strong Buy’ Stocks to Buy Today,12/23/2025, According to Top Analysts
- Midday Fly By: Ellison backstops Paramount bid for Warner Bros.
- Arcellx initiated, Cummins upgraded: Wall Street’s top analyst calls
- 3 ‘Strong Buy’ Stocks to Buy Today,12/22/2025, According to Top Analysts
- Wells starts Arcellx with Overweight on multiple myeloma potential